<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151279">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01816789</url>
  </required_header>
  <id_info>
    <org_study_id>ANDROS-01-13</org_study_id>
    <nct_id>NCT01816789</nct_id>
  </id_info>
  <brief_title>Age- Versus Ovarian Reserve Markers - Based Therapy in In Vitro Fertilization (IVF)/Intracytoplasmic Sperm Injection (ICSI) Cycles</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Andros Day Surgery Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Andros Day Surgery Clinic</source>
  <oversight_info>
    <authority>Italy: Istituto Superiore di Sanità</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized controlled trial has been designed for carrying out  a comparison of new AMH
      (Anti-Müllerian Hormone)-based individualized treatment (using a nomogram) with the wide
      accepted age-based strategy. The main objective of the trial is to assess whether an
      individualized FSH starting dose can increase the rate of women with an adequate ovarian
      response in terms of retrieved oocytes (optimal number of retrieved oocytes: 5-14).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>March 2013</start_date>
  <primary_completion_date type="Anticipated">October 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>The percentage of women with an appropriate number (N=5-14) of retrieved oocytes in IVF/ICSI cycles</measure>
    <time_frame>18 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">360</enrollment>
  <condition>In Vitro Fertilization</condition>
  <condition>Ovarian Stimulation</condition>
  <arm_group>
    <arm_group_label>Group A: &quot;age&quot;</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group A: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle, until the end of gonadotropin administration) + 150 IU of rFSH (starting dose) if female age was ≤35 years or 225 IU of rFSH if female age was ≥ 36 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B: &quot;nomogram&quot;</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Group B: long standard protocol (buserelin 0.1 ml s.c. twice per day from the 21st day of the cycle until the end of gonadotropin administration) + individualized starting dose of rFSH on the basis of the nomogram.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rFSH</intervention_name>
    <arm_group_label>Group A: &quot;age&quot;</arm_group_label>
    <arm_group_label>Group B: &quot;nomogram&quot;</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>buserelin</intervention_name>
    <arm_group_label>Group A: &quot;age&quot;</arm_group_label>
    <arm_group_label>Group B: &quot;nomogram&quot;</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  first or second IVF/ICSI attempt (the second one after 6 months from the   first
             one);regular menstrual cycles (25-33 days);female age ≤ 40; day 3 FSH ≤
             15IU/L;treatment with a long GnRH agonist protocol (buserelin)+rFSH;BMI: &gt;18 and ≤ 25
             kg/m2;presence of both ovaries.

        Exclusion Criteria:

          -  irregular cycles, anovulatory infertility, endometriosis III-IV stage AFS, use of
             adjunctive therapies for stimulation, evidence of PCO status, previous ovarian
             surgery,  presence of ovarian cysts, history of PID, use of hormonal contraception in
             the previous 3 months, any known metabolic or endocrinological disease, AMH levels &lt;
             1 and &gt; 4.0 ng/ml
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Adolfo Allegra, MD</last_name>
    <phone>+39 091 6785537</phone>
    <email>allegra@centroandros.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angelo Marino, MD</last_name>
    <phone>+39 091 6785537</phone>
    <email>marino@centroandros.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>ANDROS Day Surgery Clinic</name>
      <address>
        <city>Palermo</city>
        <state>Sicily</state>
        <zip>90144</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adolfo Allegra, MD</last_name>
      <phone>+39 091 6785537</phone>
      <email>marino@centroandros.it</email>
    </contact>
    <investigator>
      <last_name>Adolfo Allegra, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 22, 2013</lastchanged_date>
  <firstreceived_date>March 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Starting dose</keyword>
  <keyword>rFSH</keyword>
  <keyword>controlled</keyword>
  <keyword>ovarian</keyword>
  <keyword>stimulation</keyword>
  <keyword>IVF/ICSI</keyword>
  <keyword>cycles</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Buserelin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
